The breast cancer resistance protein, also known as ABCG2, is one of the most highly studied ATP-binding cassette (ABC) transporters because of its ability to confer multidrug resistance 1,2 . The lack of information on the physiological role of ABCG2 in humans severely limits cancer chemotherapeutic approaches targeting this transporter. We report here that ABCG2 comprises the molecular basis of a new blood group system (Junior, Jr) and that individuals of the Jr(a−) blood type have inherited two null alleles of ABCG2. We identified five frameshift and three nonsense mutations in ABCG2. We also show that the prevalence of the Jr(a−) blood type in the Japanese and European Gypsy populations is related to the p.Gln126* and p.Arg236* protein alterations, respectively. The identification of ABCG2 −/− (Jr(a−)) individuals who appear phenotypically normal is an essential step toward targeting ABCG2 in cancer and also in understanding the physiological and pharmacological roles of this promiscuous transporter in humans.
In an accompanying paper 3 , we have determined the genetic basis of the Lan(−) blood type and thus identified individuals homozygous for null mutations in ABCB6, which encodes another ABC transporter family member. This work allowed us to investigate the physiological role of this ABC transporter and highlighted the need for a comprehensive understanding of blood types to fully realize the goals of personalized medicine.
As part of an effort to identify the genes encoding the few remaining high-frequency blood group antigens with an unknown molecular basis, we focused our research on Junior antigen a (Jr a ). The corresponding anti-Jr a alloantibody may appear after the immunization of individuals who do not express Jr a and hence have the Jr(a−) blood type. Anti-Jr a antibody may be responsible for acute hemolytic transfusion reactions 4 but is of particular concern in obstetrics, as it can cause fatal hemolytic disease of the fetus and newborn (HDFN) 5 . In fact, anti-Jr a antibody is usually detected during pregnancy in Jr(a−) mothers, whose Jr(a−) blood type remains unrecognized until they develop anti-Jr a antibody in response to the Jr(a+) cells of their fetus. Although the Jr(a−) blood type is rare worldwide, many cases have been found in the Japanese population 6, 7 and in European Gypsy communities 5, 8 . Transfusion support of Jr(a−) individuals is highly difficult to manage because of the extreme rarity of Jr(a−) blood donors. A monoclonal antibody specific for Jr a , HMR0921 (Fig. 1a) , has been available since 1994 (ref. 7) but has not led to the elucidation of the genetic basis of this blood group antigen. In particular, we were unable to immunoprecipitate Jr a with HMR0921 from human red blood cells (RBCs), either because of the low abundance of Jr a or the low affinity of HMR0921.
Exploring the existence of Jr a in different mammalian species by analyzing their RBCs by flow cytometry, we observed that the RBCs from most species showed no reactivity with HMR0921 ( Supplementary  Fig. 1 ), but cat RBCs showed much stronger reactivity with HMR0921 than human RBCs (Fig. 1a,b) . We therefore decided to identify the antigen recognized by HMR0921 on cat RBCs, assuming it would eventually lead to the identification of the corresponding human Jr a blood group antigen. A protein of approximately 70 kDa was efficiently immunoprecipitated by HMR0921 in cat RBCs (Fig. 1c) and was identified by mass spectrometry as Abcg2 (Supplementary Fig. 2) , encoded by the cat ortholog of the human transporter gene ABCG2. To determine whether human ABCG2 similarly encodes Jr a , we transfected an ABCG2 expression construct into K-562 erythroleukemia cells, which do not express this transporter 9 , and first analyzed them by flow cytometry. We observed strong expression of ABCG2 as well as of Jr a at the surface of ABCG2-transfected K-562 cells (Fig. 1d) . We then used these cells to immunoprecipitate ABCG2 with HMR0921 (Fig. 1e) , ultimately showing that the human Jr a blood group antigen is carried by ABCG2. Together these data establish that ABCG2 (at chromosome 4q22) defines a new blood group system.
Initially discovered on the basis of being highly expressed in placenta 10 as well as conferring anthracyclin or mitoxantrone resistance in MCF-7 breast cancer cells 11, 12 , the plasma membrane transporter ABCG2 has since been shown to confer multidrug resistance in several cancer cells by actively exporting a wide variety of drugs across the plasma membrane 1, 3 . Under normal conditions, ABCG2 is thought to have an important role in protecting the organism against various toxic substances by restricting absorption or facilitating elimination, as shown by the characterization of Abcg2 −/− mice 13 . Consistently, ABCG2 is expressed in barrier tissues, such as intestine and placenta, as well as in the blood-brain barrier 14 . ABCG2 is also highly expressed on the canalicular membrane of hepatocytes 14 and the brush border membrane of renal proximal tubular cells 15 and, in addition, is well known to be expressed on hematopoietic stem cells 9 and mature RBCs 16 . Because of the potential impact of altered ABCG2 function on the bioavailability or pharmacokinetics of its numerous drug substrates, ABCG2 has been the subject of intense pharmacogenetic studies 17 . Hence, several hundred ABCG2 polymorphisms have been reported to date in the NCBI dbSNP database (build 132).
To determine which ABCG2 polymorphisms are responsible for the Jr(a−) blood type, we sequenced ABCG2 in a cohort of 18 unrelated Jr(a−) individuals (see Online Methods for details). We found nonsense and frameshift mutations in ABCG2 in all analyzed Jr(a−) subjects, and identified 8 different ABCG2 mutations altogether (Fig. 2a, Table 1 and Supplementary Fig. 3a-h ). Most of these Jr(a−) subjects were homozygous for a single ABCG2 mutation, whereas the others were heterozygous for two mutations (Supplementary Table 1 ), which strongly suggested that the Jr(a−) blood type results from recessive inheritance of ABCG2 null mutations. We first verified recessive inheritance by analyzing pedigrees of the Jr(a−) probands ( Supplementary Fig. 4) . We then confirmed the absence of the ABCG2 transporter in Jr(a−) individuals by protein blot analysis of RBC membrane lysates (Fig. 2b) and flow cytometry analysis of native (Fig. 2c) . On the basis of these data, we concluded that the ABCG2 mutations identified in the Jr(a−) subjects correspond to null alleles of ABCG2 and are responsible for the Jr(a−) blood type. Despite the large number of reported polymorphisms within ABCG2, the eight null mutations we identified were not present in NCBI dbSNP, except for the c.376C>T nonsense mutation (encoding p.Gln126*). This mutation was initially discovered in a heterozygous state in searching for nonsynonymous SNPs in ABCG2 in the Japanese population 18 and was later found in the Korean population 19 , which is consistent with our results (Supplementary Table 1 , subjects YAN, KAN and LEV). Furthermore, with an estimated frequency of 1.6-2.4% in Japan 18, 20 , the c.376C>T mutation may by itself account for the frequency of the Jr(a−) blood type in the Japanese population (0.026-0.066%) 6, 7 .
Six out of the seven unrelated Jr(a−) subjects who were homozygous for the c.706C>T nonsense mutation (encoding p.Arg236*) (Supplementary Table 1 , subjects GIM, PAT, BENO, REI, REN and KAR) belonged to Gypsy communities of southwestern Europe, suggesting that the c.706C>T mutation is the genetic basis of the Jr(a−) blood type in this population. These six Jr(a−) subjects shared the same ABCG2 haplotype (Supplementary Table 1) , consistent with the hypothesis of a founder mutation in an ancestral allele. However, the c.706C>T mutation was also found on another haplotype in two other Jr(a−) subjects not of Gypsy origin (Supplementary Table 1 , subjects BOU and BER), suggesting that this mutation has arisen independently twice.
The discovery of ABCG2 −/− (Jr(a−)) individuals is an essential step toward understanding the physiological role of ABCG2 in humans. To pursue this goal, we first evaluated the plasma levels of urate in Jr(a−) individuals, as genome-wide association studies (GWAS) of large cohorts have recently identified the minor allele at rs2231142 in ABCG2 (encoding the defective Q141K variant 18, 21 ) as a risk factor for hyperuricemia and gout 22, 23 and revealed the capacity of ABCG2 to transport urate 24 . We used cryopreserved plasma samples from pregnant Jr(a−) women (see Online Methods for details) and observed that the levels of urate were not significantly elevated in the absence of ABCG2 (220 ± 50 µmol/l (N = 9) for ABCG2 −/− versus 214 ± 76 µmol/l (N = 9) for controls). This result indicated that urate homeostasis is not markedly impaired in pregnant ABCG2 −/− women and suggested that other mechanisms may compensate for the absence of ABCG2. Alternatively, this unexpected result may reflect important differences in hormonal control. Indeed, a study reported that the c.376C>T null mutation in ABCG2 is strongly associated with risk of hyperuricemia and gout in Japanese men 25 , and it was suggested that men homozygous for this mutation may be at higher risk because of their complete deficiency in ABCG2. Future studies to validate this hypothesis should be greatly facilitated by our demonstration here that men homozygous for the c.376C>T mutation have the Jr(a−) blood type and represent a significant fraction of the Japanese population 6, 7 .
Because knockout mouse studies indicated an essential role of ABCG2 in maintaining porphyrin homeostasis in RBCs 16, 26 , we examined porphyrin levels in the blood of Jr(a−) individuals. We procured fresh Jr(a−) blood samples during the monitoring of pregnancies of Jr(a−) women. Consistent with the suspected role of ABCG2 in exporting excess porphyrin from RBCs 16, 26 , the porphyrin levels in the plasma were very low and in fact undetectable in Jr(a−) blood samples (<5.0 nmol/l (N = 3), where the normal range is 6.5-20.0 nmol/l), and the porphyrin levels in RBCs were elevated (3.3 ± 1.7 µmol/l (N = 3) , where the normal range is 0.1-1.9 µmol/l), although not tenfold higher as observed in Abcg2 −/− mice 26 . These data should be confirmed outside of pregnancy and in larger cohorts but suggest that, although ABCG2 −/− individuals show no symptoms of porphyria 27 , they do have aberrations in porphyrin transport that may place them at risk under certain conditions. Of note, the ABCB6 transporter also contributes to porphyrin export from RBCs 3 and may compensate, albeit not fully, for the absence of ABCG2 in humans.
In addition to the immediate impact on transfusion medicine and obstetrics, identifying the genetic basis of the Jr(a−) blood type has uncovered a significant number of individuals who lack the promiscuous ABCG2 transporter. These ABCG2 −/− (Jr(a−)) individuals are expected to be hypersensitive to the drugs transported by ABCG2, and our ability to identify them by blood typing is of major clinical interest in order to predict drug responses and to establish optimal and more personalized drug dosages.
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npg oNLINE METhods
Subjects. The cohort of 18 Jr(a−) subjects analyzed in this study corresponds to all the Jr(a−) probands who had been investigated at the CNRGS and from whom a frozen blood sample was still available; these blood samples are primarily used for serological investigations when an antibody against a highfrequency blood group antigen has been detected. Of note, all 18 subjects were women whose Jr(a−) blood type had been identified during pregnancy after they had developed anti-Jr a antibodies. Fresh blood samples were taken after obtaining informed consent, and the study was conducted according to the ethical standards of the INTS.
Animal blood samples. Animal blood samples were taken according to the ethical standards of the Enra.
HMR0921 monoclonal antibody.
The production and characterization of the HMR0921 monoclonal antibody to Jr a has previously been described in detail 7 . Briefly, peripheral blood lymphocytes from a healthy Japanese individual whose serum contained anti-Jr a antibody (titer of 128) were transformed with Epstein-Barr virus (EBV), fused with the mouse myeloma cell line P3X63Ag8.653 using polyethylene glycol (PEG), subjected to hypoxanthine-aminopterin-thymidine (HAT)-ouabain selection and cloned by repeated limiting dilution. Hybridomas secreting anti-Jr a antibody were identified by antiglobulin tests with Jr(a+) and Jr(a−) RBCs. The HMR0921 clone was expanded for antibody production. The reactivity titer of the produced HMR0921 was 512 with native or trypsin-, α-chymotrypsin-, papain-or DTT-treated Jr(a+) RBCs, as determined by antiglobulin test.
Sequencing. The primers used to amplify and sequence ABCG2 have been described previously 19, 28, 29 and are listed in Supplementary Table 2 .
Detailed descriptions of PCR conditions are available upon request. PCR products were sequenced with ABI BigDye Terminator chemistry (GATC Biotech) after ExoSAP treatment (GATC Biotech). Sequence analysis was performed using DNA Workbench software (CLC bio). Mutations were screened by unidirectional sequencing and confirmed by bidirectional sequencing. Mass spectrometry analysis. Polyacrylamide gels were stained with the SilverQuest Silver Staining kit (Invitrogen). Excised bands were diced into small pieces, washed with water and destained with the Silver D-Stain kit (G-Biosciences). Gel pieces were subjected to two rounds of washing with water for 5 min at room temperature followed by incubation with 50% acetonitrile in 50 mM ammonium bicarbonate for 30 min at 37 °C. Gel pieces were then completely dehydrated by adding 100% acetonitrile. After removal of acetonitrile, gel pieces were dried in a speed vacuum centrifuge, placed on ice and allowed to swell with 12.5 ng/µl Sequencing Grade Modified Trypsin (Promega) in 50 mM ammonium bicarbonate for 30 min. An equal volume of 50 mM ammonium bicarbonate was added, and the samples were incubated overnight at 37 °C. Peptides were collected and gel pieces were further extracted, once with 50% acetonitrile in 2.5% formic acid and once with 100% acetonitrile. Pooled peptide extractions were dried in a speed vacuum centrifuge, and peptides were resuspended in 2.5% acetonitrile in 2.5% formic acid and loaded for nanoscale liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis in an LTQ Orbitrap mass spectrometer (ThermoElectron) as previously described 30 . Tandem mass spectra were searched against a concatenated forward and reverse human international protein index (IPI) database 31 Plasmid construction. The coding sequence of human ABCG2 cDNA was amplified from a Human Fetal Liver Marathon-Ready cDNA library (Clontech), cloned into pCR4Blunt-TOPO vector (Invitrogen), sequence verified (identical to NM_004827.2) and subcloned as a NotI-and SbfI-digested fragment into the pCEP5 episomal vector, which is a pCEP4 vector (Invitrogen) with a modified polylinker. The complete sequence of the pCEP5-ABCG2 plasmid is available upon request.
Cell culture and transfection. Human K-562 cells were grown in Iscove's modified Dulbecco's medium (IMDM + GlutaMAX-I, Gibco) supplemented with 10% fetal bovine serum (FBS; Pan-Biotech) and 0.5× antibioticantimycotic solution (Gibco) at 37 °C under a humidified atmosphere containing 5% CO 2 . Cells were periodically tested for mycoplasma contamination using a laboratory-designed PCR assay. To obtain K-562 transfectants, 1 × 10 6 K-562 cells were first transfected with 2 µg of pCEP5-ABCG2 plasmid by nucleofection using the Nucleofector II device and the Cell Line Nucleofector Kit V (Amaxa) according to the manufacturer's protocol (program T-016). Stable K-562 transfectants were obtained after 13-15 d of selection with hygromycin B (0.5 mg/ml; Invitrogen). Plasmid DNA used for transfection was purified with NucleoBond Xtra Midi Plus (Macherey-Nagel) and verified by restriction analysis before transfection.
Urate and porphyrin analysis. Urate levels were measured with a uricase method, adapted to the Dimension Clinical Chemistry System by Siemens Healthcare Diagnostics, in plasma samples that were cryopreserved at the CNRGS because they contained an alloantibody of interest. Nine plasma samples from pregnant Jr(a−) women were available; four plasma samples from pregnant Yt(a−) women and five from pregnant Lu(b-) women were npg
